

# Antonio Lupo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2399170/publications.pdf>

Version: 2024-02-01

30  
papers

1,170  
citations

567281

15  
h-index

477307

29  
g-index

30  
all docs

30  
docs citations

30  
times ranked

3472  
citing authors

#	ARTICLE	IF	CITATIONS
1	Genetic associations at 53 loci highlight cell types and biological pathways relevant for kidney function. <i>Nature Communications</i> , 2016, 7, 10023.	12.8	412
2	Genome-wide Association Studies Identify Genetic Loci Associated With Albuminuria in Diabetes. <i>Diabetes</i> , 2016, 65, 803-817.	0.6	131
3	Mitochondria: a new therapeutic target in chronic kidney disease. <i>Nutrition and Metabolism</i> , 2015, 12, 49.	3.0	96
4	NLRP3 Inflammasome Activation in Dialyzed Chronic Kidney Disease Patients. <i>PLoS ONE</i> , 2015, 10, e0122272.	2.5	70
5	Systemic and Nonrenal Adverse Effects Occurring in Renal Transplant Patients Treated with mTOR Inhibitors. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-13.	3.3	65
6	A type I interferon signature characterizes chronic antibody-mediated rejection in kidney transplantation. <i>Journal of Pathology</i> , 2015, 237, 72-84.	4.5	40
7	Monoclonal Antibody Therapy and Renal Transplantation: Focus on Adverse Effects. <i>Toxins</i> , 2014, 6, 869-891.	3.4	36
8	The relationship between calcium kidney stones, arterial stiffness and bone density: unraveling the stone-bone-vessel liaison. <i>Journal of Nephrology</i> , 2015, 28, 549-555.	2.0	35
9	A specific immune transcriptomic profile discriminates chronic kidney disease patients in predialysis from hemodialyzed patients. <i>BMC Medical Genomics</i> , 2013, 6, 17.	1.5	32
10	mTOR Inhibition Role in Cellular Mechanisms. <i>Transplantation</i> , 2018, 102, S3-S16.	1.0	26
11	Everolimus-induced epithelial to mesenchymal transition in immortalized human renal proximal tubular epithelial cells: key role of heparanase. <i>Journal of Translational Medicine</i> , 2013, 11, 292.	4.4	24
12	mTOR inhibitors and renal allograft: Yin and Yang. <i>Journal of Nephrology</i> , 2014, 27, 495-506.	2.0	23
13	Personalization of the Immunosuppressive Treatment in Renal Transplant Recipients: The Great Challenge in "Omics" Medicine. <i>International Journal of Molecular Sciences</i> , 2015, 16, 4281-4305.	4.1	23
14	Everolimus-induced epithelial to mesenchymal transition (EMT) in bronchial/pulmonary cells: when the dosage does matter in transplantation. <i>Journal of Nephrology</i> , 2016, 29, 881-891.	2.0	23
15	Red blood cells and platelet membrane fatty acids in non-dialyzed and dialyzed uremies. <i>Clinica Chimica Acta</i> , 1992, 211, 155-166.	1.1	21
16	Epithelial to mesenchymal transition in the liver field: the double face of Everolimus in vitro. <i>BMC Gastroenterology</i> , 2015, 15, 118.	2.0	15
17	Transcriptomics: A Step behind the Comprehension of the Polygenic Influence on Oxidative Stress, Immune Deregulation, and Mitochondrial Dysfunction in Chronic Kidney Disease. <i>BioMed Research International</i> , 2016, 2016, 1-16.	1.9	13
18	Dialysis-related transcriptomic profiling: The pivotal role of heparanase. <i>Experimental Biology and Medicine</i> , 2014, 239, 52-64.	2.4	12

#	ARTICLE	IF	CITATIONS
19	Sulodexide alone or in combination with low doses of everolimus inhibits the hypoxia-mediated epithelial to mesenchymal transition in human renal proximal tubular cells. <i>Journal of Nephrology</i> , 2015, 28, 431-440.	2.0	12
20	New non-renal congenital disorders associated with medullary sponge kidney (MSK) support the pathogenic role of GDNF and point to the diagnosis of MSK in recurrent stone formers. <i>Urolithiasis</i> , 2017, 45, 359-362.	2.0	10
21	Interleukin-27 is a potential marker for the onset of post-transplant malignancies. <i>Nephrology Dialysis Transplantation</i> , 2019, 34, 157-166.	0.7	9
22	A single dialysis session of hemodiafiltration with sorbent-regenerated endogenous ultrafiltrate reinfusion (HFR) removes hepcidin more efficiently than bicarbonate hemodialysis: a new approach to containing hepcidin burden in dialysis patients?. <i>Journal of Nephrology</i> , 2018, 31, 297-306.	2.0	8
23	In Vitro Identification of New Transcriptomic and miRNomic Profiles Associated with Pulmonary Fibrosis Induced by High Doses Everolimus: Looking for New Pathogenetic Markers and Therapeutic Targets. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1250.	4.1	8
24	Early Small Creatinine Shift Predicts Contrast-Induced Acute Kidney Injury and Persistent Renal Damage after Percutaneous Coronary Procedures. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 305-311.	0.8	7
25	The fate of glyoxal and methylglyoxal in peritoneal dialysis. <i>Journal of Mass Spectrometry</i> , 2006, 41, 405-408.	1.6	5
26	Assessment of physical performance and body composition in male renal transplant patients. <i>Journal of Nephrology</i> , 2018, 31, 613-620.	2.0	5
27	Nephrotic Syndrome During 2-Mercapto-Propionyl-Glycine (Thiola) Therapy. <i>Nephron</i> , 1981, 28, 96-99.	1.8	3
28	Influence of haemodialysis on the NT-proBNP plasma concentration. <i>Clinical Chemistry and Laboratory Medicine</i> , 2007, 45, 1414-5.	2.3	3
29	Single-side renal sympathetic denervation to treat malignant refractory hypertension in a solitary kidney patient. <i>Journal of Nephrology</i> , 2014, 27, 713-716.	2.0	3
30	SP783IMPACT OF THE MAINTENANCE IMMUNOSUPPRESSIVE THERAPY ON THE FECAL MICROBIOME OF RENAL TRANSPLANT RECIPIENTS: COMPARISON BETWEEN AN EVEROLIMUS- VERSUS A STANDARD TACROLIMUS-BASED REGIMEN. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i607-i607.	0.7	0